Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.
Surrozen was founded by five leading-edge scientists: K. Christopher Garcia, Ph.D., Roel Nusse, Ph.D. and Calvin Kuo, M.D., Ph.D. from Stanford University; Claudia Janda, Ph.D. from the Princess Maxima Center for Pediatric Oncology; and Hans Clevers, M.D, Ph.D. from the Hubrecht Institute and Princess Maxima Center. Each has conducted extensive research on Wnt signaling, with findings that together shape Surrozen’s technology and approach to therapeutic development. The company is backed by The Column Group, a leading biotechnology venture capital firm.
We are currently seeking highly creative scientists to join our team, and invite you to explore career opportunities on our website.
Surrozen was founded by five leading-edge scientists: K. Christopher Garcia, Ph.D., Roel Nusse, Ph.D. and Calvin Kuo, M.D., Ph.D. from Stanford University; Claudia Janda, Ph.D. from the Princess Maxima Center for Pediatric Oncology; and Hans Clevers, M.D, Ph.D. from the Hubrecht Institute and Princess Maxima Center. Each has conducted extensive research on Wnt signaling, with findings that together shape Surrozen’s technology and approach to therapeutic development. The company is backed by The Column Group, a leading biotechnology venture capital firm.
We are currently seeking highly creative scientists to join our team, and invite you to explore career opportunities on our website.
Total raised: $133M
Founded date: 2016
Investors 4
| Date | Name | Website |
| 10.07.2026 | 5AM Ventur... | 5amventure... |
| - | The Column... | thecolumng... |
| - | Timefolio ... | timefolioc... |
| - | SymBiosis | symbiosis.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 19.06.2020 | Series C | $50M | - |
| 14.03.2019 | Series B | $50M | - |
| 15.02.2017 | Series A | $33M | - |
Mentions in press and media 7
| Date | Title | Description |
| 25.11.2021 | TCG Announces the Addition of TCG iPartners | TCG’s iPartners represents a new ideation advisory group comprised of leading academic investigators and biotech entrepreneurs. Working closely with TCG’s Swanson Fellows and our core investment team, this group is dedicated to crafting inn... |
| 18.03.2019 | Term Sheet — Monday, March 18 | ON THE ROAD Ride-hailing company Lyft begins its road show today, and it’s aiming high. The startup hopes to raise a maximum of $2.4 billion from its public debut at a valuation that could reach $23 billion. The company will offer a little ... |
| 18.03.2019 | Surrozen Secures $50M in Series B Financing | Surrozen Inc., a San Francisco, CA-based biopharmaceutical company, secured $50m in Series B financing. Backers included Horizons Ventures, Hartford HealthCare Endowment, NS Investment and the Column Group. Proceeds from the financing will ... |
| 15.03.2019 | Daily funding roundup - March 15th, 2019 | Aeponyx raised $5.9M; UPshow raised $6M; ArangoDB raised $10M; Zeus Living raised $24M Aeponyx: Aeponyx is a fabless micro optical switch semiconductor chips designer and manufacturer. Aeponyx has raised C$7.9 million ($5.9 million) in Seri... |
| 15.03.2019 | Surrozen Raises $50M in Series B Financing | SAN FRANCISCO, CA, Surrozen announced the successful completion of a $50 million Series B financing. >> Click here for more funding data on Surrozen >> To export Surrozen funding data to PDF and Excel, click here Surrozen... |
| 15.02.2017 | Surrozen Raises $33M in Series A Financing | Surrozen, Inc., a South San Francisco, CA-based biopharmaceutical company focused on discovering and developing drugs that promote the repair and regeneration of human tissues, closed a $33m Series A financing. The round was led by The Colu... |
| - | The Column Group Raises a $725 Million Fourth Fund | The Column Group (TCG), a biotech venture capital firm focused on building innovative drug discovery companies, announced the closing of The Column Group IV (TCG IV) and its related investment vehicles totaling $725 million. With TCG IV, th... |